Evidence map›Paper›PMID 30655971›Full record

ReviewMolecular and clinical oncology2019

Hematological malignancies during pregnancy.

Merav Barzilai, Irit Avivi, Odelia Amit

Abstract readReview
In one paragraph

Review in Molecular and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Awareness on hematological malignancies among college students.Journal of advanced pharmaceutical technology & research · 2022
    Article
  4. Review
  5. Management Challenges of Acute Promyelocytic Leukemia in Pregnancy: A Case Report.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Merav BarzilaiHematology and Hemato-Oncology Division, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.
Irit AviviHematology and Hemato-Oncology Division, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.
Odelia AmitHematology and Hemato-Oncology Division, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematological malignancy during pregnancy is a rare event, therefore most data on this issue is based on case studies, retrospective studies and expert opinion. The purpose of the present narrative review was to provide an overview of the diagnosis and recommended management of the most common hematological malignancies during pregnancy, based on current literature, with clinical cases, and discussion of the diagnostic and therapeutic options. The therapeutic consensus while coping with hematological malignancies in pregnancy is to salvage the mother, while trying to preserve pregnancy and avoid treatment-related-toxicity to the fetus. In most scenarios, particularly during late trimesters, the goal is to administer the same treatment as outside of pregnancy, if possible. Further research is needed for better evidence-based management.

Indexed as

hematological malignancieshemotherapy during pregnancyimaging during pregnancymalignancy during pregnancy

Identifiers

PMID30655971
PMCPMC6313953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.